A Study Assessing KB707 for Cancer Treatment
Phase 1/2
240
about 3.8 years
18+
15 sites in CA, FL, IN +8
About this study
This trial is testing a new treatment called KB707 in people with advanced cancer. The goal is to see if KB707 is safe and helps fight the cancer. Participants will receive KB707, either alone or with other medications like Opdualag or Keytruda, depending on their specific situation.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive KB707
- 2.Take KEYTRUDA ®( Pembrolizumab)
- 3.Take Opdualag
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
immunotherapy (PD-1 inhibitor immunotherapy (pembrolizumab)), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Percentage of adverse events (AEs), Percentage of serious adverse events (SAEs)
Secondary: Maximum tolerated dose (MTD), Percentage of overall response rate (ORR)
Oncology